2022 Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have
December 14, 2022
December 14, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with atopic dermatitis.
2022 has been a banner year for patients with pediatric atopic dermatitis (AD) as well as for their parents, families, and healthcare providers. The biologic dupilumab was approved for moderate to severe AD for ages 6 months to 5 years. Adolescents with AD also got new treatment options with approvals of oral systemic and topical JAK inhibitors, upadacitinib and ruxolitinib, respectively. There are also biologics and JAK inhibitors that are now in phase 3 clinical trials for children and adolescents with AD.
Join pediatric AD expert, Dr. Peter Lio, as he discusses pivotal trials from 2022 to highlight the new and emerging treatment for children and adolescents with AD.
Upon completion of this activity, participants should be better able to:
- Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications
- Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD
Peter Lio, MD
Clinical Assistant Professor
Department of Dermatology & Pediatrics
Partner, Medical Dermatology Associates
Physician Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
- Peter Lio, MD
- Advisory Board: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KP Away), Burt’s Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, Leo Pharma, Level Ex, Lipidor AB, L'Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, Yobee Care
- Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
- Patent Holder: Theraplex AIM (patent pending)
- Speaker: AbbVie, Eli Lilly, Galderma, Incyte, Leo Pharma, L'Oréal, Pfizer, Regeneron/Sanofi Genzyme
- Stock Options: Altus Labs, Boston Skin Science (KP Away), Concerto Biosciences, LearnSkin, Micreos, Yobee Care
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of December 14, 2022 through December 14, 2023, participants must:
- Read the learning objectives.
- Complete the pretest.
- Study the educational activity.
- Complete the posttest and the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.